—Validation of IndiGO risk prediction model reopens cardiovascular risk debate—
Alpharetta, GA— Population Health Management leader SPH Analytics’ IndiGO® solution was the subject of a recent study in the American Journal of Managed Care. The results confirm the potential for preventing additional heart attacks and strokes by following IndiGO’s predictive analytics and treatment recommendations. The paper also validated the high accuracy of IndiGO’s underlying statistical models. The study followed more than a million members of a large health plan for a period of three years to reach its conclusions.
Co-author of the study, Dr. Macdonald “Don” Morris, PhD, Chief Scientific Officer of SPH Analytics said, “These results are particularly relevant in light of the adoption of calculated cardiovascular risk as the basis for prescribing statins. This study should give users of IndiGO confidence that their prevention decisions are based on accurate risk estimates and that patients’ risks are not being overlooked because the models do not enable their risk to be calculated.”
According to the Centers for Disease Control, statins are one of the most commonly prescribed classes of drugs and are used by more than 25% of adults over the age of 40. Since national guidelines started using risk to determine who should receive statins, there have been ongoing concerns within the medical community about the accuracy of the risk calculations and whether this might lead to the wrong patients receiving treatment. These concerns were recently underscored by a paper in the May issue of the Journal of the American College of Cardiology. Lead author, Rana Tabada, and team reported that the cardiovascular risk calculator currently in standard use overestimated risk by up to five-fold.
SPH Analytics uses the IndiGO risk-prediction model, based on more than 20 years of patient data and advanced algorithms, to give providers and patients information about their risk of developing chronic conditions and the impact of recommended interventions on preventing or managing these chronic conditions.
“IndiGO’s ability to help providers prioritize their clinical population using powerful analytics ensures that the right patients are receiving the right treatment. I appreciate the amount of work that went into validating the tool and look forward to working with healthcare leaders who want a more accurate method of addressing risk and engaging patients in the care that is best for their needs,” said Dr. Bill O’Connor, Chief Medical Officer of SPH Analytics.
About SPH Analytics
SPH Analytics (SPHA) is a leader in population health management and action analytics, providing best-in-class solutions and transformative technologies for provider, payer, and health networks. By providing powerful applications, analytics, healthcare surveys, call center services, and consulting, SPHA solutions lead the way for the next generation of healthcare. SPHA enables clients to increase member and patient satisfaction, improve population health, drive patient engagement, and reduce overall cost of care. SPHA solutions incorporate an engaging social-media style user experience, optimized for mobility and communication, to measure data, create easy-to-understand analytics, and empower action.
Founded through the merger of Voyance, MDdatacor, Archimedes Clinical Analytics, and The Myers Group, SPH Analytics is based in Alpharetta, GA, with offices in Branford, CT, San Francisco, CA, Nashville, TN, and Duluth, GA. SPH Analytics is a member of the $3 billion Symphony Technology Group. For more information, call 1-866-460-5681 or visit SPHAnalytics.com.
CAHPS® is a registered trademark of the Agency for Healthcare Research and Quality.
The post Accuracy of SPH Analytics’ Clinical Risk Prediction Tool Validated by Study appeared first on SPH Analytics.